NOVEN ANNOUNCES RESULTS OF 2002 ANNUAL SHAREHOLDERS' MEETING

Miami, FL, May 16, 2002 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the results of its 2002 Annual Meeting of Shareholders, held yesterday, May 15, at its corporate headquarters in Miami, Florida.

The holders of over 95% of Noven's common stock were represented in person or by proxy at the meeting. Shareholders re-elected the following persons to the Noven Board of Directors:

* Sidney Braginsky (President & CEO of Atropos Technology Inc.);
* John G. Clarkson, M.D. (Senior Vice President for Medical Affairs & Dean, University of Miami School of Medicine);
* Lawrence J. DuBow (Chairman, HMS Sales and Marketing, Inc.);
* Regina E. Herzlinger (Prof. of Business Administration, Harvard Business School);
* Robert C. Strauss (President, CEO & Chairman of Noven); and
* Wayne P. Yetter (CEO & Chairman, SYNAVANT, Inc.).

Shareholders also ratified the appointment of Deloitte & Touche as Noven's independent auditors for 2002. At the meeting, Robert Strauss made a presentation regarding Noven's business and prospects. A replay of the presentation and the proceedings of the meeting is available on the Internet at http://www.noven.com.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a highly profitable women's health products company called Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot®, licensed to Novogyne, and Estradot®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch®, licensed to Novogyne, and Estalis®, licensed to Novartis Pharma AG). With a range of additional products in development, including once-daily MethyPatch® for Attention Deficit Hyperactivity Disorder, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal drug delivery systems.

 

Investor & Media Contact:
Stefaney Davis
Noven Pharmaceuticals, Inc.
(305) 964-3182

 

 

Copyright ©  2002 Noven Pharmaceuticals, Inc. All rights reserved.